These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28810322)

  • 21. Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.
    Qin YZ; Jiang Q; Jiang H; Lai YY; Zhu HH; Liu YR; Jiang B; Huang XJ
    Medicine (Baltimore); 2016 Jan; 95(2):e2486. PubMed ID: 26765457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative Analysis of Efficacy and Drug Resistance of Imatinib in Patients with Chronic Myeloid Leukemia at Chronic and Advanced Phases].
    Wang W; Liu HB; Zhang M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1039-43. PubMed ID: 27531771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
    Abou Dalle I; Kantarjian H; Burger J; Estrov Z; Ohanian M; Verstovsek S; Ravandi F; Borthakur G; Garcia-Manero G; Jabbour E; Cortes J
    Cancer Med; 2019 Nov; 8(15):6559-6565. PubMed ID: 31502383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
    Bao X; Qiu H; Chen S; Ma X; Tang X; Fu C; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):553-8. PubMed ID: 26304076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
    Jiang Q; Qin Y; Lai Y; Jiang H; Shi H
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):7-13. PubMed ID: 26876246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Effect and Safety of Flumatinib in Patients with Chronic Myelogenous Leukemia Failed First-and Second-line Treatment].
    Liu LY; Wei JF; Jia T; Mao JP; Cai ZM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):370-375. PubMed ID: 38660838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China.
    Deng M; Guan X; Wen X; Xiao J; An X; Yu J
    Medicine (Baltimore); 2020 Feb; 99(7):e19150. PubMed ID: 32049841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
    J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
    Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):728-736. PubMed ID: 38049316
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
    Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
    Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
    Wang YY; Zhao HG; Cui ZG; Li GL; Shi X; Xu H; Zhou Y; Zhao T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):356-63. PubMed ID: 25948185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
    Ćojbašić I; Mačukanović-Golubović L; Vučić M; Ćojbašić Ž
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e526-e531. PubMed ID: 31239209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
    Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
    Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
    Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
    Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
    Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
    Zhang XS; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):54-62. PubMed ID: 35231994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.